Association between serum interleukin-6 and frailty in older men: cross-sectional data
Tóm tắt
To investigate the association between serum interleukin-6 (IL-6) and frailty. There is evidence that suggests that IL-6 is positively associated with frailty in men; an association partly explained by medications known to affect inflammation. These findings support the notion that frailty is a state of heightened inflammation and that IL-6 could be a potential biomarker useful for identifying individuals that are at risk of frailty. To investigate the association between serum interleukin-6 (IL-6) and frailty. Participants were 581 men aged 60–90 yr (median (IQR): 74 yr (67–83 yr)) from the Geelong Osteoporosis Study. Tallies of ≥ 3, 1–2 and 0 for weight loss/exhaustion/physical-inactivity/slowness/weakness indicated frailty, pre-frailty and robustness, respectively. Anthropometry, lower-limb muscle strength and physical performance were measured and health behaviours self-reported. Serum IL-6 was measured using an enzyme-linked immunosorbent assay and log-transformed (ln-IL-6). Total antioxidant capacity (TAC) was also measured using quantitative colorimetric determination. Multivariable ordinal logistic regression models tested associations between ln-IL-6 and frailty while considering age, anthropometry, comorbidities, TAC, medications that affect inflammatory processes, lifestyle and socioeconomic status. There were 49(8.4%) frail and 315(54.2%) pre-fail men. A relationship was evident between ln-IL-6 and frailty before and after accounting for age (adjusted OR = 1.24, 95%CI 1.01–1.53). Adjusting for medications attenuated the association (OR = 1.20, 95%CI 0.98–1.48). No other confounders were identified. These data suggest that IL-6 is positively associated with frailty in men, partly explained by advancing age and medications known to affect inflammation.
Tài liệu tham khảo
Chen X, Mao G, Leng SX (2014) Frailty syndrome: an overview. Clin Interv Aging 9:433–441
Iqbal J, Denvir M, Gunn J, Clegg A, Young J, Iliffe S et al (2013) Frailty in elderly people. Lancet 381(9868):752–762
Milte R, Crotty M (2014) Musculoskeletal health, frailty and functional decline. Best Pract Res Clin Rheumatol 28(3):395–410
Fedarko NS (2011) The biology of aging and frailty. Clin Geriatr Med 27:27–37
Yao X, Li H, Leng SX (2011) Inflammation and immune system alterations in frailty. Clin Geriatr Med 27(1):79–87
Fried L, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol Ser A 56(3):M146–M156
Baylis D, Bartlett DB, Syddall HE, Ntani G, Gale CR, Cooper C et al (2013) Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people. Age (Omaha) 35(3):963–971
Gale CR, Baylis D, Cooper C, Sayer AA (2013) Inflammatory markers and incident frailty in men and women: the english longitudinal study of ageing. Age (Omaha) 35(6):2493–2501
Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R et al (2016) Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev 31:1–8
Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP et al (2020) Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta-analysis. GeroScience 42(6):1451–1473
Pasco JA, Nicholson GC, Kotowicz MA (2012) Cohort profile: geelong osteoporosis study. Int J Epidemiol 41(6):1565–1575
Brennan-Olsen SL, Williams LJ, Holloway KL, Hosking SM, Stuart AL, Dobbins AG et al (2015) Small area-level socioeconomic status and all-cause mortality within 10years in a population-based cohort of women: data from the geelong osteoporosis study. Prev Med Reports 2:505–511
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
Dent E, Kowal P, Hoogendijk EO (2016) Frailty measurement in research and clinical practice: a review. Eur J Intern Med 31:3–10
Marino M, Nicholas JA, Gleim GW, Rosenthal P, Nicholas SJ (1982) The efficacy of manual assessment of muscle strength using a new device. Am J Sports Med 10(6):360–364
Pasco JA, Stuart AL, Holloway-Kew KL, Tembo MC, Sui SX, Anderson KB et al (2020) Lower-limb muscle strength: normative data from an observational population-based study. BMC Musculoskelet Disord 21(1):89
Podsiadlo D, Richardson S (1991) The timed “Up and Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142–148
Tembo MC, Holloway-Kew KL, Bortolasci CC, Sui SX, Brennan-Olsen SL, Williams LJ et al (2020) Total antioxidant capacity and frailty in older men. Am J Mens Health 14(5):8–23
Tembo MC, Holloway-Kew KL, Sui SX, Dunning T, Low ACH, Yong SJ et al (2020) Prevalence of frailty in older men and women: cross-sectional data from the Geelong Osteoporosis Study. Calcif Tissue Int 107:220–229
Leng SX, Tian X, Matteini A, Li H, Hughes J, Jain A et al (2011) Il-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults. Age Ageing 40(4):475–481
Puts MTE, Visser M, Twisk JWR, Deeg DJH, Lips P (2005) Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol (Oxf) 63(4):403–411
Dinarello CA (2010) Anti-inflammatory agents : present and future. Cell 140(6):935–950